Indications And Dose
DOSE EQUIVALENCE AND CONVERSION There is no evidence to show that any one oral preparation of mesalazine is more effective than another; however, the delivery characteristics of oral mesalazine preparations may vary. ASACOL ® MR 400MG TABLETS Treatment of mild to moderate ulcerative colitis, acute attack ▶BY MOUTH ▶Child 12–17 years: 800 mg 3 times a day ▶Adult: 2.4 g daily in divided doses Maintenance of remission of ulcerative colitis and Crohn’s ileo-colitis ▶BY MOUTH ▶Child 12–17 years: 400–800 mg 2–3 times a day ▶Adult: 1.2–2.4 g daily in divided doses ASACOL ® MR 800MG TABLETS Treatment of mild to moderate ulcerative colitis, acute attack ▶BY MOUTH ▶Adult: 2.4–4.8 g daily in divided doses Maintenance of remission of ulcerative colitis ▶BY MOUTH ▶Adult: Up to 2.4 g once daily, alternatively up to 2.4 g daily in divided doses Maintenance of remission of Crohn’s ileo-colitis ▶BY MOUTH ▶Adult: Up to 2.4 g daily in divided doses ASACOL ® FOAM ENEMA Treatment of acute attack of mild to moderate ulcerative colitis affecting the rectosigmoid region ▶BY RECTUM ▶Adult: 1 g daily for 4–6 weeks, to be administered into the rectum Treatment of acute attack of mild to moderate ulcerative colitis, affecting the descending colon ▶BY RECTUM ▶Adult: 2 g once daily for 4–6 weeks, to be administered into the rectum ASACOL ® SUPPOSITORIES Treatment of acute attack of mild to moderate ulcerative colitis and maintenance of remission ▶BY RECTUM ▶Adult: 0.75–1.5 g daily in divided doses, last dose to be administered at bedtime MEZAVANT ® XL Treatment of mild to moderate ulcerative colitis, acute attack ▶BY MOUTH ▶Adult: 2.4 g once daily, increased if necessary to 4.8 g once daily, review treatment at 8 weeks Maintenance of remission of ulcerative colitis ▶BY MOUTH ▶Adult: 2.4 g once daily OCTASA ® Treatment of mild to moderate ulcerative colitis, acute attack Gastro-intestinal system ▶BY MOUTH ▶Adult: 2.4–4.8 g once daily, alternatively 2.4–4.8 g daily in divided doses, dose over 2.4 g daily in divided doses only Maintenance of remission of ulcerative colitis and Crohn’s ileo-colitis ▶BY MOUTH ▶Adult: 1.2–2.4 g once daily, alternatively daily in divided doses PENTASA ® GRANULES Treatment of mild to moderate ulcerative colitis, acute attack ▶BY MOUTH ▶Child 5–17 years (body-weight up to 40 kg): 10–20 mg/kg 3 times a day ▶Child 5–17 years (body-weight 40 kg and above): 1–2 g twice daily, total daily dose may alternatively be given in 3–4 divided doses ▶Adult: Up to 4 g once daily, alternatively up to 4 g daily in 2–4 divided doses Maintenance of remission of ulcerative colitis ▶BY MOUTH ▶Child 5–17 years (body-weight up to 40 kg): 7.5–15 mg/kg twice daily, total daily dose may alternatively be given in 3 divided doses ▶Child 5–17 years (body-weight 40 kg and above): 2 g once daily ▶Adult: 2 g once daily PENTASA ® RETENTION ENEMA Treatment of acute attack of mild to moderate ulcerative colitis or maintenance of remission ▶BY RECTUM ▶Adult: 1 g once daily, dose to be administered at bedtime Treatment of acute attack of mild to moderate ulcerative colitis affecting the rectosigmoid region ▶BY RECTUM ▶Child 12–17 years: 1 g once daily, dose to be administered at bedtime PENTASA ® SUPPOSITORIES Treatment of acute attack, ulcerative proctitis ▶BY RECTUM ▶Adult: 1 g daily for 2–4 weeks Maintenance, ulcerative proctitis ▶BY RECTUM ▶Adult: 1 g daily PENTASA ® TABLETS Treatment of mild to moderate ulcerative colitis, acute attack ▶BY MOUTH ▶Adult: Up to 4 g once daily, alternatively up to 4 g daily in 2–3 divided doses Maintenance of remission of ulcerative colitis ▶BY MOUTH ▶Adult: 2 g once daily SALOFALK ® ENEMA Treatment of acute attack of mild to moderate ulcerative colitis or maintenance of remission ▶BY RECTUM ▶Adult: 2 g once daily, dose to be administered at continued → bedtime SALOFALK ® GRANULES Treatment of mild to moderate ulcerative colitis, acute attack Gastro-intestinal system ▶BY MOUTH ▶Child 5–17 years (body-weight up to 40 kg): 30–50 mg/kg once daily, dose preferably given in the morning, alternatively 10–20 mg/kg 3 times a day ▶Child 5–17 years (body-weight 40 kg and above): 1.5–3 g once daily, dose preferably given in the morning, alternatively 0.5–1 g 3 times a day ▶Adult: 1.5–3 g once daily, dose preferably taken in the morning, alternatively 0.5–1 g 3 times a day Maintenance of remission of ulcerative colitis ▶BY MOUTH ▶Child 5–17 years (body-weight up to 40 kg): 7.5–15 mg/kg twice daily, total daily dose may alternatively be given in 3 divided doses ▶Child 5–17 years (body-weight 40 kg and above): 500 mg 3 times a day ▶Adult: 500 mg 3 times a day SALOFALK ® RECTAL FOAM Treatment of mild ulcerative colitis affecting sigmoid colon and rectum ▶BY RECTUM ▶Child 12–17 years: 2 g once daily, dose to be administered into the rectum at bedtime, alternatively 2 g daily in 2 divided doses ▶Adult: 2 g once daily, dose to be administered into the rectum at bedtime, alternatively 2 g daily in 2 divided doses SALOFALK ® SUPPOSITORIES Treatment of acute attack of mild to moderate ulcerative colitis affecting the rectum, sigmoid colon and descending colon ▶BY RECTUM ▶Adult: 0.5–1 g 2–3 times a day, adjusted according to response, dose to be given using 500 mg suppositories Treatment of acute attack of mild to moderate ulcerative colitis affecting the rectum ▶BY RECTUM ▶Adult: 1 g daily, preferably at bedtime, dose to be given using 1 g suppositories SALOFALK ® TABLETS Treatment of mild to moderate ulcerative colitis, acute attack ▶BY MOUTH ▶Child 5–17 years (body-weight up to 40 kg): 10–20 mg/kg 3 times a day ▶Child 5–17 years (body-weight 40 kg and above): 0.5–1 g 3 times a day ▶Adult: 0.5–1 g 3 times a day Maintenance of remission of ulcerative colitis ▶BY MOUTH ▶Child 5–17 years (body-weight up to 40 kg): 7.5–15 mg/kg twice daily, total daily dose may alternatively be given in 3 divided doses ▶Child 5–17 years (body-weight 40 kg and above): 500 mg 3 times a day ▶Adult: 500 mg 3 times a day l UNLICENSED USE ▶With oral use in children Asacol ® (all preparations) not licensed for use in children under 18 years. Pentasa ® granules and Salofalk ® tablets and granules not licensed for use in children under 6 years. ▶With rectal use in children Salofalk ® rectal foam no dose recommendations for children (age range not specified by manufacturer).
PDF pages 67, 68